Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subxyphoid Epicardial/Endocardial Hybrid Atrial Fibrillation Ablation and Left Atrial Appendage (LAA) Exclusion Approach for Patients With Persistent and Longstanding Persistent Atrial Fibrillation Registry

NCT04148625 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04148625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04148625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subxyphoid Epicardial/Endocardial Hybrid Atrial Fibrillation Ablation and Left Atrial Appendage (LAA) Exclusion Approach for Patients With Persistent and Longstanding Persistent Atrial Fibrillation Registry
Lead sponsor
University of California, San Francisco
Phase
Observational
Overall status
Enrolling by invitation
Start date
September 14, 2016
Completion date
June 30, 2026
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, persistent